regeneron pharmaceuticals
(RGO:Munich Stock Exchange)
RGO
Industry Average
Profitability - regeneron pharmaceuticals (RGO)
|
Return on Assets Industry Comparison
20.29%
|
Return on Equity Industry Comparison
87.68%
|
|
|
Return on Capital Industry Comparison
26.14%
|
Margin Analysis - regeneron pharmaceuticals (RGO)
|
Gross Margin Industry Comparison
51.57%
|
Levered Free Cash Flow Margin Industry Comparison
-14.31%
|
|
|
EBITDA Margin Industry Comparison
39.49%
|
SG&A Margin Industry Comparison
14.47%
|
Asset Turnover - regeneron pharmaceuticals (RGO)
|
Total Assets Turnover Industry Comparison
0.9x
|
Accounts Receivables Turnover Industry Comparison
3.0x
|
|
|
Fixed Assets Turnover Industry Comparison
4.2x
|
Inventory Turnover Industry Comparison
30.6x
|
Credit Ratios - regeneron pharmaceuticals (RGO)
|
Current Ratio Industry Comparison
6.6x
|
Quick Ratio Industry Comparison
5.6x
|
Long-Term Solvency - regeneron pharmaceuticals (RGO)
|
Total Debt/Equity Industry Comparison
32.9x
|
Total Liabilities/Total Assets Industry Comparison
38.2x
|
Growth Over Prior Year - regeneron pharmaceuticals (RGO)
|
Total Revenue Industry Comparison
180.57%
|
Tangible Book Value Industry Comparison
179.02%
|
|
|
EBITDA Industry Comparison
-672.36%
|
Gross Profit Industry Comparison
7,842.42%
|
|
|
Receivables Industry Comparison
236.75%
|
Inventory Industry Comparison
609.31%
|
|
|
Diluted EPS Before Extra Industry Comparison
-511.41%
|
Capital Expenditures Industry Comparison
29.02%
|
|
|
Cash From Ops. Industry Comparison
-145.23%
|
Levered Free Cash Flow Industry Comparison
41.49%
|
| Recently Viewed | |||
| RGO:GR | €191.92 EUR | -5.08 |  |
| Company | Last | Change |
| Alkermes PLC | $32.94 USD | -0.065 |
| Allergan Inc/United States | $98.05 USD | +0.09 |
| BioMarin Pharmaceutical Inc | $64.65 USD | -1.11 |
| Onyx Pharmaceuticals Inc | $95.20 USD | -1.00 |
| Vertex Pharmaceuticals Inc | $78.09 USD | -0.39 |
| View Industry Companies | ||
Industry Analysis
RGO
Industry Average
| Valuation | RGO | Industry Range |
| Price/Earnings | 35.2x |
|
| Price/Sales | 15.6x |
|
| Price/Book | 17.6x |
|
| Price/Cash Flow | 29.8x |
|
| TEV/Sales | 15.3x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact REGENERON PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
